- Valbiotis announces completion of recruitment for the Phase II/III REVERSE-IT clinical study with TOTUM•63 against prediabetes, in partnership with Nestlé Health Science.
- The Jacquet plant in Saint-Beauzire (Limagrain group) is committed to reducing its water consumption by 15% with the signing of the PURE plan (IN FRENCH).
- Valbiotis announces the major success of the Phase II HEART clinical study: the patented plant-based active substance TOTUM•070 proves its efficacy against hypercholesterolemia, a cardiovascular risk factor.
